Key Metrics of Emnar Pharma Private Limited
About Emnar Pharma Private Limited
Sectors
Company details
- Registered office
- Plot No: A - 4, Mch No: 7 - 2 - A4,, Industrial Estate,, Opp. Sanath Nagar Police Station,, Sanath Nagar,, Hyderabad, In-ts, 500018
Operational Areas of Emnar Pharma Private Limited
Company summary
Entity details
Compliance
Industry classification
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingFiling compliance
Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit ratings
WatchIssuer not cooperating with ICRA (rating based on limited information)
Rating history
Rating actions
| Date | Agency | Action | Long term | Short term | Outlook | Rated amount | Rationale |
|---|---|---|---|---|---|---|---|
| 12 Oct 2026 | ICRA | Non-cooperating | B+ | A4 | Stable | ₹69.3 Cr | View |
EMNAR PHARMA PRIVATE LIMITED (EPPL), formerly known as Emmennar Bio-tech Private Limited is engaged in manufacture of API intermediates. The company started operations in 2005 with a manufacturing facility for Methyl Isothiocyanate (MITC) and N-Methyl-1 and (methylthio)-2-Nithromethanamin (NMSM) which are intermediates for Ranitidine Hcl. Later, in 2011 the company began commercial production of Tramadol Hcl out of a newly commissioned facility in Jawahar Lal Nehru Pharma City (JNPC), Vishakhapatnam. During FY 13, Emmennar Bio-tech Private Limited merged with its group company - ECPL effecting a backward integration into manufacture of intermediates for Tramadol Hcl. Name of the merged entity was later changed to Emmennar Pharma Private Limited. The company is part of Virch ow Group which comprises of seven API and drug intermediate manufacturing units, one biotech and one engineering unit.
Borrowings & rated debt
Facility mix
Rated facilities
| Facility | Type | Previous | Current | Change | Rating | Action | Agency |
|---|---|---|---|---|---|---|---|
| Fund-based continues to remain under ‘Issuer | Working capital & bank lines | ₹40.0 Cr | ₹40.0 Cr | 0.0% | — | Other | ICRA |
| Non-fund based continues to remain under ‘Issuer Not | Non-fund based limits | ₹5.30 Cr | ₹5.30 Cr | 0.0% | — | Other | ICRA |
| Unallocated ISSUER NOT limits continues to remain under ‘ ’ | Other | ₹24.0 Cr | ₹24.0 Cr | 0.0% | A4 | Non-cooperating | ICRA |
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Not cooperating since 12 Oct 2026 (0 months) |
| Credit enhancement | None – standalone rating |
| Next action stable or better (model) | 20% |
| Information on file | 22% · missing: Audited financial statements (last 18 months), Annual results history (3+ years), Liquidity position, Debt obligations and repayment schedule, Capex / investment plans, Auditor details, Shareholding pattern |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Borrowing & funding lifecycle
- Credit outlook model: 39% chance the next rating action is stable or better
- Current rating B+ (below investment grade)
- ₹23.95 cr of rated limits not yet tied to a lender
- Issuer not cooperating with the rating agency
Rated limits by facility
Timeline
Lender names, bank charges and audited borrowings are part of Premium.
Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.
Registered office and contact
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Emnar Pharma Private Limited
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
 Torrent Pharmaceuticals |
Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | torrentpharma.com | 1959 | Ahmedabad, India |
| APIs & Bulk Drugs · Pharmaceuticals & Healthcare | piramalpharma.com | — | Mumbai, Maharashtra, India | |
| GLAND PHARMA LTD | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Hyderabad, Telangana, India |
| Alivira Animal Health Limited | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Maharashtra, India |
| Viyash Scientific | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Hyderabad, India |
| ALIVUS LIFE SCIENCES LIMITED | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Solapur, Maharashtra, India |
| Anuh Pharma Limited | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Mumbai, India |
| Aarey Drugs And Pharmaceuticals Limited | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Thane, Maharashtra, India |
| DCM Shriram Fine Chemicals Limited | APIs & Bulk Drugs · Pharmaceuticals & Healthcare | — | — | Delhi, India |
| APIs & Bulk Drugs · Pharmaceuticals & Healthcare | tevapharm.com | — | India |
Similar companies
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Pharmaceuticals, APIs and formulations
Filings
No filings on record yet.